Pazopanib for metastatic soft-tissue sarcoma (PALETTE) : a randomised, double-blind, placebo-controlled phase 3 trial

Autor: van der Graaf WT, Blay, Jy, Chawla, Sp, Kim, Dw, Bui Nguyen, B, Casali, Pg, Schöffski, P, Aglietta, Massimo, Staddon, Ap, Beppu, Y, Le Cesne, A, Gelderblom, H, Judson, Ir, Araki, N, Ouali, M, Marreaud, S, Hodge, R, Dewji, Mr, Coens, C, Demetri, Gd, Fletcher, Cd, Dei Tos AP, Hohenberger, P, EORTC Soft Tissue, Bone Sarcoma Group, PALETTE study group

Publikováno v: The Lancet (London), 379, 1879-86
The Lancet (London), 379, 9829, pp. 1879-86
Lancet, 379(9829), 1879-1886

Item does not contain fulltext BACKGROUND: Pazopanib, a multitargeted tyrosine kinase inhibitor, has single-agent activity in patients with advanced non-adipocytic soft-tissue sarcoma. We investigated the effect of pazopanib on progression-free survi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e504ee0ea9c1bc33830fe09e5cdb03b4
https://www.ncbi.nlm.nih.gov/pubmed/22595799

Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial.

Autor: Verweij J (AUTHOR), Casali PG (AUTHOR), Zalcberg J (AUTHOR), LeCesne A (AUTHOR), Reichardt P (AUTHOR), Blay J (AUTHOR), Issels R (AUTHOR), van Oosterom A (AUTHOR), Hogendoorn PCW (AUTHOR), Van Glabbeke M (AUTHOR), Bertulli R (AUTHOR), Judson I (AUTHOR), EORTC (European Organisation for Research and Treatment of Cancer) Soft Tissue and Bone Sarcoma Group (CORPORATE AUTHOR), Italian Sarcoma Group (CORPORATE AUTHOR), Australasian Gastrointestinal Trials Group (CORPORATE AUTHOR)

Publikováno v: Lancet. 9/25/2004, Vol. 364 Issue 9440, p1127-1134. 8p.

iCREATE: imaging features of primary and metastatic alveolar soft part sarcoma from the EORTC CREATE study.

Autor: Mcaddy NC; Department of Radiology, The Royal Marsden Hospital, London, UK. nmcaddy@gmail.com., Saffar H; Department of Radiology, The Royal Marsden Hospital, London, UK., Litière S; Soft Tissue and Bone Sarcoma Group, European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium., Jespers P; Soft Tissue and Bone Sarcoma Group, European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium., Schöffski P; Department of General Medical Oncology and Department of Oncology, KU Leuven, Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium.; The Institute of Cancer Research, London, UK., Messiou C; Department of Radiology, The Royal Marsden Hospital, London, UK.; Soft Tissue and Bone Sarcoma Group, European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium.; The Institute of Cancer Research, London, UK.

Publikováno v: Cancer imaging : the official publication of the International Cancer Imaging Society [Cancer Imaging] 2020 Oct 30; Vol. 20 (1), pp. 79. Date of Electronic Publication: 2020 Oct 30.

Testing new regimens in patients with advanced soft tissue sarcoma: analysis of publications from the last 10 years.

Autor: Penel N; European Organisation for Research and Treatment of Cancer Headquarters, EORTC, Brussels, Belgium; Oscar Lambret Comprehensive Cancer Centre and Lille-Nord-de-France University, Lille, France; European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group, EORTC, Brussels, Belgium. Electronic address: n-penel@o-lambret.fr., Van Glabbeke M; European Organisation for Research and Treatment of Cancer Headquarters, EORTC, Brussels, Belgium; European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group, EORTC, Brussels, Belgium., Marreaud S; European Organisation for Research and Treatment of Cancer Headquarters, EORTC, Brussels, Belgium; European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group, EORTC, Brussels, Belgium., Ouali M; European Organisation for Research and Treatment of Cancer Headquarters, EORTC, Brussels, Belgium; European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group, EORTC, Brussels, Belgium., Blay JY; European Organisation for Research and Treatment of Cancer Headquarters, EORTC, Brussels, Belgium; European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group, EORTC, Brussels, Belgium; Léon Bérard Comprehensive Cancer Centre, University Claude Bernard Lyon I, Lyon, France., Hohenberger P; European Organisation for Research and Treatment of Cancer Headquarters, EORTC, Brussels, Belgium; European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group, EORTC, Brussels, Belgium; Division of Surgical Oncology and Thoracic Surgery, Department of Surgery, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany.

Publikováno v: Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2011 Jun; Vol. 22 (6), pp. 1266-1272. Date of Electronic Publication: 2010 Dec 23.

Phase II study of raltitrexed ('Tomudex') for patients with advanced soft tissue sarcomas refractory to doxorubicin-containing regimens.

Autor: Blay JY; EORTC Soft Tissue and Bone Sarcoma Group, Brussels, Belgium. blay@lyon.fnclcc.fr, Judson I, Rodenhuis S, Hermans C, Smith M, van Glabbeke M, Verweij J

Publikováno v: Anti-cancer drugs [Anticancer Drugs] 1999 Nov; Vol. 10 (10), pp. 873-7.